Hepatology

Article	Citations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	2233
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	1923
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	1739
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	1191
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	464
Late-Breaking Abstracts	325
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	277
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	252
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention	241
Cover Image	213
Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!	212
Letter to the editor: The precise relationship between MELD and survival without a liver transplant	197
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency	190
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet	188
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST	184
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8	184
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis	181
Honey, I shrunk the tumor: Downstaging HCC before liver transplantation	168
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	160
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	152
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	151
Access to technology to support telehealth in areas without specialty care for liver disease	147
Reply	145
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	133
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	126

Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease	124
Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD	124
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	122
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	122
Letter to the Editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis	119
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	116
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1	116
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients	113
Reply: Timing shapes adjuvant PD-1 efficacy after hepatectomy in HCC	111
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	108
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	106
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	105
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	104
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	102
Regulatory role and translational potential of CCL11 in liver fibrosis	102
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH	102
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	101
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	100
Efficacy and safety of infliximab in patients with autoimmune hepatitis	98
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	96
	96
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	96
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	95
Genes that fit just right: Unzipping the genome of fatty liver disease	94
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?	92
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm	92
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?	90
Reply	90
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	89
Reply: The CRAPT-M score: Robust enough for clinical practice?	89
	89
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism	88
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans	88
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats	87
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	87
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation	85
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	85
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis	82
Letter to the Editor: Overlooking the important factor: Hypoxia	80
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known	78
Letter to the editor	76
The digital determinants of liver disease	75
Instructions to Authors	75
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis	74
Letter to the Editor: Insights into immune-mediated adverse events and survival outcomes—Lessons from HIMALAYA	73
The international quest for the imaging diagnosis of liver cancer	73
Healthy peribiliary glands are necessary for successful liver transplantation	73
Reply: Diabetes and fibrosis—Parallel risks or overlap?	73
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity	72
Much more needed in natural history of Alagille syndrome	72

Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty	70
In vivo imaging of calcium dynamics in zebrafish hepatocytes	70
Letter to the editor: Is PAI‐1 a thrombotic biomarker in NASH cirrhosis?	69
Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness	69
Interleukin 8-CXCR2–mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap–induced stellate cell activation	67
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma	67
Fontan‐associated liver disease	66
Erratum	66
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination	66
Therapeutic manipulation of the microbiome in liver disease	66
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease	65
Letter to the Editor: Screening and risk stratification disparities in Hispanic MASLD	64
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	64
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	64
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	64
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries’ framework for digital twin advancement	63
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men	63
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response	62
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis	61
Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome	61
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH	61
Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms	60
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature	60
Dedifferentiation‐associated inflammatory factors of long‐term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment	60
Emergence of highly profibrotic and proinflammatory Lrat + Fbln2 + HSC subpopulation in alcoholic hepatitis	60
The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer	59
NAFLD‐related hepatocellular carcinoma: The growing challenge	58
Metabolic dysfunction-associated steatotic liver disease and the heart	58
A strategy of vascular‐targeted therapy for liver fibrosis	58
Immunobiology of primary sclerosing cholangitis	58
The clot and the complicated consult	57
Serum amyloid A1–induced intrahepatic regulatory T-cell dysfunction drives autoimmune hepatitis progression	55
The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in managing metabolic dysfunction–associated steatotic liver disease	55
Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease	54
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis	54
Early detection of primary liver cancer using plasma cell‐free DNA fragmentomics: Do all the pieces come together?	54
Glutamine synthetase loss in β-catenin–mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming	53
Reply	53
Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block	53
Manuscript best practices: Takeaways from a community conversation	53
The “shell game” after objective response in patients with advanced HCC treated with immunotherapy	52
Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort	52
Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia	52
Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	52
Reply	52
SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling	52
Reply	52
Reply	52
Hepatology Highlights	51
Letter to the Editor: Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	51
Letter to Editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function	50
Letter to the editor: RECAM for the diagnosis of DILI—Is it time to incorporate additional pharmacological criteria?	50
Letter to the editor: Considerations on the use of the liver transplant comorbidity index (LTCI)	50
Reply	50
Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study—Sh	49
Integrative Hepatology: Enhancing overall health to manage liver disease	49
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC	48
Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	48
The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent	48
Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution	47
Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases	47
HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylation	47
Natural history and development of a novel composite endpoint in patients with alcohol-associated hepatitis: Data from a prospective multicenter study	47
Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS	47
Reply: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD	46
Letter to the Editor: Exchangeable copper in the Danish cohort of patients with Wilson disease	46
Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with “Ludwig disease”	46
A bright future: Sustainable treatment of gastric varices	46
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States	45
PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features	45
Letter to the Editor: Peripheral Foxp3-high Tregs as a dual biomarker for HCC prognosis and immunotherapy response	45
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study	45
Myeloid CD36 deficiency alleviates hepatic fibrosis by promoting adaptive immunity of macrophage	45
Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis through extracellular vesicles	44
AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation	44
Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease	44
Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis	44
HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy	44
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation	44
Future directions in acute liver failure	43

Pathway to global elimination of hepatitis B: HBV cure is just the first step	43
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study	43
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study	42
Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?	42
Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and co-therapy with allopurinol	42
Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices	42
Intrahepatic cholangiocarcinoma PANoptosidy	41
More than a lark? LRRK2 inhibitors to treat alpha-1 antitrypsin deficiency	41
Predicting liver outcomes with biomarker monitoring in MASLD	41
Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions	41
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors	41
Masthead	41
Letter to the editor: High rate of clinical and immunological response in patients with HCV‐associated cryoglobulinemia	40
Letter to the Editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma	40
Reply	40
Letter to the Editor: Re-examining neoadjuvant chemoradiation plus transplantation versus liver resection for de novo perihilar cholangiocarcinoma	40
Reply: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD	40
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab–bevacizumab	40
Reply: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis?	40
Masthead	40
Multicentered study of patient outcomes after declined for early liver transplantation in severe alcohol-associated hepatitis	40
Corticosteroids for high‐grade immune checkpoint inhibitor–mediated hepatitis: Is less more?	39
Erratum for Ren, H et al. Sirtuin 2 prevents liver steatosis and metabolic disorders by deacetylation of hepatocyte nuclear factor 4α	39
Cover Image	39
Letter to the Editor: Is right heart assessment vital for evaluating terlipressin-related outcomes in hepatorenal syndrome-acute kidney injury?	39
Letter to the editor: Relevance of population‐based cutoffs to define frailty in clinical studies	39
Reply	39
Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!	38
Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury	38
What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west	38
Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality	38
Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease	38
Letter to the editor: HuR in liver homeostasis	38
Reply: Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: accuracy and routine variables are the success keys	38
The Liver Meeting: 2025 Abstracts	38
Letter to the Editor: More questions than answers—Response to the POP-NEXT project	38
Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination‐deficient hepatocellular carcinoma	37
Letter to the Editor: Key advance in noninvasive fibrosis assessment: Evidence from China	37
Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis	37
Letter to the Editor: The profile of HBsAg levels after nucleos(t)ide analogues treatment is crucial for achieving a functional cure	37
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase	37
Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study	36
Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI	36
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon	36
A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis	36
Letter to the Editor: There may be a misunderstanding about the function of circular RNA as miRNA sponges	36
Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study	35
Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV‐specific T‐cell response and homing	35
Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease	35
Tripartite motif‐containing protein 31 confers protection against nonalcoholic steatohepatitis by deactivating mitogen‐activated protein kinase kinase kinase 7	35
Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population	35
A global action agenda for turning the tide on fatty liver disease	35
Imaging for better responses to immunotherapy in hepatocellular carcinoma	35
Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs	34
Telehealth interventions in patients with chronic liver diseases: A systematic review	34
Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial	34
Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure	34
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC	34
Prognostic significance of mild ascites in patients with cirrhosis	34
Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study	34
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations	34
Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC	34
Hepatocyte‐derived MASP1‐enriched small extracellular vesicles activate HSCs to promote liver fibrosis	34
Letter to the editor: Loss of Sam50 in hepatocytes induces cardiolipin‐dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury	33
The macrophage STING-YAP axis controls hepatic steatosis by promoting the autophagic degradation of lipid droplets	33
Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy	33
The evolving role of liver sinusoidal endothelial cells in liver health and disease	33
Category Index	33
A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver D	33
Category Index	33
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations	33
Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis	33
Letter to the Editor: Use of HBV RNA and to predict change in serological status and disease activity in CHB	32
BileMet: A new frontier in distinguishing malignant from benign biliary conditions	32
RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1-mutated hepatocellular carcinoma	32
Reply: Revisiting FOXP3 expression and its prognostic implications in hepatocellular carcinoma	32
Multimodal multiphasic preoperative image-based deep-learning predicts HCC outcomes after curative surgery	32
Dynamic duo: Spleen stiffness and bilirubin revolutionize PSVD screening	32
Letter to the Editor: Re-evaluating the clinical relevance of the RIPPLY1-TBX19 axis in CTNNB1-mutant hepatocellular carcinoma	32
Benefit and harm of waiting time in liver transplantation for HCC	32
Gut-to-bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders	31
Integrative single-cell and spatial transcriptomic analyses identify a pathogenic cholangiocyte niche and TNFRSF12A as therapeutic target for biliary atresia	31
Epigenetic heterogeneity hotspots in human liver disease progression	30
CAD manipulates tumor intrinsic DHO/UBE4B/NF-κB pathway and fuels macrophage cross-talk, promoting HCC metastasis	30
Autophagy promotes hepatic cystogenesis in polycystic liver disease by depletion of cholangiocyte ciliogenic proteins	30
Hepatitis D virus—still the devil!	30
Combinatorial targeting of G‐protein‐coupled bile acid receptor 1 and cysteinyl leukotriene receptor 1 reveals a mechanistic role for bile acids and leukotrienes in drug‐induced liver injury	30
Targeting mTORC2-Dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET-activated and β-catenin-mutated hepatocellular carcinoma	30
The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC	30
Erratum: IL-6–induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma	30
Letter to the Editor: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis	30
Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries	30
Technical systematic review supporting 2025 AASLD practice guidelines on management of chronic hepatitis B	30
Reply: More on nonalcoholic/nonmetabolic dysfunction–associated steatohepatitis	30
Letter to the Editor: Dynamic frailty trajectories and temporal measurement challenges in assessing liver transplantation survival benefit	30